Obalon To Present at Two Upcoming Institutional Investor Conferences

SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for weight loss, announces that Bill Plovanic, President and Chief Executive Officer, will present corporate overviews at the following investor conferences:

Stifel 2019 Healthcare Conference                                                                                

Wednesday, November 20, 2019, Presentation time 9:10am ET                     
Lotte New York Palace Hotel, New York City                                                                                                         
Webcast Available at:

Canaccord Genuity Medical Technologies & Diagnostics Forum

Thursday, November 21, 2019, Presentation time 2:00pm ET                                                           
The Westin Grand Central Hotel, New York City                                                                                                           
Webcast Available at:

Live audio webcasts of the presentation can be accessed through the links above. Replays of the webcasts will be available for 90 days following each presentation.

About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit

For Obalon Therapeutics, Inc.

Investor Contact:
Bill Plovanic
President & Chief Executive Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103



Source: Obalon Therapeutics, Inc.

The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click onSafety Information and Patient Labeling